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Th  e estrogen deprivation associated with the adjuvant 
aromatase inhibitors (AIs) has been shown to increase 
the risk of bone loss and fragility fractures. Minimizing 
treat  ment toxicities and preserving bone health are 
important aspects of adjuvant breast cancer care.
Markopoulos and colleagues performed a phase III 
multicenter clinical trial investigating the aﬀ  ect of the oral 
bisphosphonate, risedronate, on bone mineral density 
(BMD) changes in postmenopausal women with hormone 
receptor (HR)-positive early-stage breast cancer receiving 
adjuvant anastrozole [1]. Th  is study – given the moniker 
ARBI – enrolled women with HR-positive early-stage 
breast cancer scheduled to receive adjuvant anastrozole 
1 mg daily, and the study participants were stratiﬁ  ed into 
three categories based on their baseline BMD. Th  ose  with 
BMD of at least –1.0 (low risk for fracture) were treated 
with anastrozole without bisphos  phonate therapy. Th  ose 
with BMD of at least –2.0 were treated with anastrozole 
plus risedronate 35 mg weekly (higher risk for fracture). 
Th  e women to receive anastro  zole with BMD less than 
–1.0 but greater than –2.0 were considered at inter  mediate 
risk for fracture and were randomized to either risedronate 
35 mg weekly or control. All patients received calcium and 
vitamin D supple  men  tation.
Th  e study design of the ARBI study, like those of the 
ARIBON [2] and SABRE [3] trials, is extremely practical. 
Th  e study participants are postmenopausal women and 
the drug, dose and schedule of the study intervention are 
couched in the literature for managing bone mass in 
postmenopausal women. Each of these three studies 
categorizes the patients’ risk of fragility fracture by BMD 
into a low, intermediate or higher risk group and assigns 
the study bisphosphonate accordingly. Th   e threshold for 
the intermediate group in the ARIBON trial (T score = 
–1.0 to –2.5) diﬀ  ers slightly from that of the other two 
studies (T score = –1.0 to –2.0), and each of the three 
studies randomized the intermediate group to bisphos-
phonate or not. Th  e studies each use an oral bisphos-
phonate, risedronate or ibandronate, in doses and 
schedules that are US Food and Drug Administration 
(FDA) approved for the prevention and treatment of 
postmenopausal osteoporosis. Th   ese three studies 
directly test whether an existing regimen for managing 
bone health is suﬃ   cient to manage BMD in postmeno-
pausal women with breast cancer receiving adjuvant AI 
therapy. All three studies are of short duration (2 years) 
and are powered for changes in BMD, a surrogate for 
fracture risk. Th  ese studies were not designed to assess 
changes in fracture rates or in the risk of breast cancer 
recurrence. Th  e changes in BMD in these three studies 
are outlined in Table 1 and are generally positive, demon-
strating that the oral bisphosphonates are able to preserve 
bone mass in the setting of adjuvant anastrozole.
Th   e use of oral bisphosphonate therapy has been well 
established as an eﬃ   cacious means of managing BMD in 
postmenopausal osteoporosis [4]. Both the ARIBON and 
SABRE trials demonstrated that the patients receiving 
oral bisphosphonate therapy experienced either stabiliza-
tion of or an increase in BMD at 2 years. In the ARBI 
study, however, there were was evidence of slight bone 
Abstract
The use of adjuvant aromatase inhibitors is associated 
with an increased risk of osteoporosis and fractures. 
The oral bisphosphonate, risedronate – dosed as 
the US Food and Drug Administration approved for 
the treatment or prevention of postmenopausal 
osteoporosis – appears to mitigate bone loss 
associated with 2 years of adjuvant anastrozole in 
women with early-stage breast cancer.
© 2010 BioMed Central Ltd
Managing bone mineral density with oral 
bisphosphonate therapy in women with breast 
cancer receiving adjuvant aromatase inhibition
Catherine Van Poznak*
See related research by Markopoulos et al., http://breast-cancer-research.com/content/12/2/R24
EDITORIAL
*Correspondence: cvanpoz@umich.edu
University of Michigan, Comprehensive Cancer Center, 1500 E. Medical Center 
Drive, C346 Med Inn Building, Ann Arbor MI  48109-5848, USA
Van Poznak Breast Cancer Research 2010, 12:110 
http://breast-cancer-research.com/content/12/3/110
© 2010 BioMed Central Ltdloss in the hip of those in the higher risk category 
receiving risedronate, and the diﬀ  erence between the two 
arms in the intermediate group was modest. Th  e  diﬀ  er-
ence between hip BMD in the inter  mediate group 
therapies may relate to the ARBI sample size, which was 
based on the expected diﬀ  erences between the random-
ized groups. Th   irty-six patients per arm were planned for 
the hip BMD analysis; at the 2-year analysis, however, the 
intermediate risk arm had 26 patients in the anastrozole 
plus risedronate arm and 21 patients in the anastrozole 
only arm. Factors that may have also aﬀ  ected the results 
include poor compliance with bis  phosphonate therapy, 
although the ARBI trial included compliance assessment 
at each follow-up visit and missed tablets were reported 
by <10% of the study patients. Compliance is a concern 
with oral bisphosphonate therapy, as was shown in a 
cohort study of 8,822 women prescribed risedronate 
(daily or weekly) in which 31% of the patients were 
noncompliant after 1 year of treatment [5]. Compliance 
and persistence rates may vary inter  nationally; the 
compliance with oral bisphosphonate at 1 year appears to 
vary between 58 and 74% in the United States, the United 
Kingdom and France [6].
Zoledronic acid and the intravenously administered 
form of ibandronate are FDA approved for the manage-
ment of low bone mass. Intravenous administration 
within the medical oﬃ     ce assures the clinician conﬁ  r-
mation of drug delivery. Th   e data supporting the use of 
intravenous bisphosphonate therapy in the manage  ment 
of AI-induced bone loss in women receiving an AI for 
early-stage HR-positive breast cancer includes zoledronic 
acid 4 mg administered every 6 months for 3 to 5 years 
[7-9]. Th  is bisphosphonate regimen has demon  strated 
the ability to maintain bone mass in this setting. It is 
notable that the FDA-approved dosing of zoledronic acid 
in the management of low bone mass is 5 mg annually 
when treating osteoporosis and is 5 mg every 2 years 
when treating postmenopausal osteopenia, and that 
Brown and colleagues demonstrated a 4 to 5% increase in 
BMD at 3 years with a single zoledronic acid dose of 4 mg 
in patients with osteopenia after cancer therapy given 
with curative intent [10]. Th   e optimal dose and interval 
of zoledronic acid to manage BMD in the setting of AI 
therapy have not been deﬁ  ned.
Th  e clinical trials investigating women at risk for 
chemotherapy-induced amenorrhea have studied both 
oral and intravenous bisphosphonates. Th  e results of 
these studies have for the most part demonstrated that 
the bisphosphonates preserve BMD [11]. One phase III 
study of risedronate 35 mg weekly versus placebo in this 
younger patient population, however, demonstrated that 
BMD loss in the lumbar spine and hip at 1 year was 
similar in both arms [12]. Although the ARBI, ARIBON, 
and SABRE trials have demonstrated that bisphos  pho-
nates dosed as the FDA has approved for the treatment 
or prevention of postmenopausal osteoporosis can 
control loss of BMD in the setting of adjuvant AI use, the 
study by Hines and colleagues raises the question of 
whether the bone loss associated with chemotherapy-
induced amenorrhea may respond less well to risedronate 
35 mg weekly. Longer follow-up and additional studies 
will shed light on the management of BMD in this 
younger patient population.
In conclusion, when managing patients with breast 
cancer receiving adjuvant AI therapy, the bisphospho-
nates may be viewed as a supportive therapy to treat or 
prevent osteoporosis. Th   e data support treating 
individuals with osteo  porosis, but the threshold for 
initiating pharmacologic interventions for osteopenia is 
less well deﬁ  ned.  Th  e ARBI study presents clinically 
useful data on the manage  ment of bone mass in women 
with breast cancer receiv  ing adjuvant AI therapy. In 
addition to managing BMD, adjuvant bisphosphonate 
therapy may provide antitumor aﬀ  ects.  Studies 
Table 1. Changes in bone mineral density in the ARBI, ARIBON and SABRE trials
  Percentage change in BMD at 2 yearsb
 Lumbar  spine  Hip
     Intermediate  Intermediate    Intermediate  Intermediate
      risk on  risk on      risk on  risk on 
Study  Osteoclast  Low no  bisphosphonate  High  Low no  bisphosphonate  High
(accrual) inhibitora risk  bisphosphonate  (P value)  risk   risk  bisphosphonate   (P value)  risk
ARBI [1]   Risedronate 
(n = 213)  35 mg weekly   (–) 2.5  (–) 1.5  (+) 5.7 (0.006)   (+) 6.6  (–) 5.7  (–) 3.9  (+) 1.6 (0.037)  (–) 1.9
ARIBON [2]   Ibandronate
(n = 131)  150 mg monthly  (–) 4.79  (–) 3.22  (+) 2.98 (<0.01)  (+) 3.52  (–) 3.72  (–) 3.90  (+) 0.60 (<0.01)  (+) 2.49
SABRE [3]   Risedronate
(n = 234)  35 mg weekly  (–) 2.1  (–) 1.8  (+) 2.2 (<0.0001)  (+) 3.0  (–) 0.4  (–) 1.1  (+) 1.8 (<0.0001)  (+) 2.0
Percentage change in bone mineral density (BMD) from baseline in postmenopausal women with early-stage breast cancer receiving adjuvant anastrozole with or 
without oral bisphosphonate therapy. aAll patients received calcium + vitamin D. bLow risk, study arm that is at low risk of osteoporotic fracture (anastrozole alone); 
intermediate risk, study arm that is at intermediate risk for osteoporotic fracture (anastrozole with bisphosphonate or not); high risk, study arm that is at higher risk for 
osteoporotic fracture (anastrozole and bisphosphonate). (+), increase; (–), decrease.
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regimens for their anticancer eﬀ  ects are ongoing, and 
their results are eagerly awaited.
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